British multinational GlaxoSmithKline has said ovarian cancer drug Zejula (niraparib) met its primary endpoint in a Phase 3 trial.
Zejula showed a statistically significant improvement in progression free survival in women with first-line ovarian cancer who had undergone platinum-based chemotherapy regardless of their biomarker status. The safety and tolerability of the drug was consistent with previous clinical trials.